Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Why Is Celgene (CELG) Up 6.1% Since Last Earnings Report?

Celgene (CELG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mitchell Moore headshot

What Investors Need to Know About the Celgene, Amgen & Bristol-Myers Deals

On Monday, Celgene (CELG) announced a sale of its psoriasis drug Otezla for $13.4 billion to Amgen (AMGN). This deal will be all cash and is expected to clear before the end of the year. Celgene's stock climbed 3.2% the day of the announcement and has risen another 0.5% since then.

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More

Key highlights of the past week include drug approvals, and other regulatory and pipeline news.

Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion

Bristol-Myers' (BMY) multiple myeloma drug, Empliciti gets approval in Europe in combination with Celgene's Pomalyst in third or later-line settings.

Alexion Wins EC Nod for Soliris in Nervous System Disorder

Alexion (ALXN) receives EC approval for the label expansion of lead drug, Soliris, for the indication of rare, devastating disorder of the central nervous system.

Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy?

Amgen's (AMGN) purchase of Celgene's blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space.

Company News for Aug 27, 2019

Companies in the news are: AMGN, PBI, BYND, SRCI, PDCE

Sweta Killa headshot

Amgen to Buy Celgene's Otezla: 5 ETF Drugs

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

Tirthankar Chakraborty headshot

3 Cancer Treatment Stocks to Enrich Your Portfolio

Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.

Alexion (ALXN) Down 3.2% After Amgen Buys Otezla From Celgene

Alexion's (ALXN) shares dip after gaining steam on rumors of a potential acquisition by Amgen last week.

Bristol-Myers Announces Sale of Celgene's Otezla to Amgen

Bristol-Myers (BMY) announces that Celgene will sell psoriasis drug, Otezla, to Amgen in connection with the ongoing regulatory approval process.

The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron

The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron

BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA

The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.

Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More

Key highlights of the past week include drug approvals, and other regulatory and pipeline news.

Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer

Celgene's (CELG) oncology portfolio gets a boost with the FDA approval of Inrebic for rare bone marrow cancer.

Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?

Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.

Agios Rides High on Tibsovo Sales Amid Acute Competition

Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.

Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat

Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.

Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

Mergers & Acquisitions Take Center Stage in Biotech Industry

Mergers & acquisitions are in focus in the biotech industry as it undergoes a wave of consolidation.

Kalyan Nandy headshot

Top Stock Reports: Micron, Sinopec, Celgene & More

Today's Research Daily features updated research reports on 16 major stocks, including Micron Technology (MU), Sinopec (SNP) and Celgene (CELG).

Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO

In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.

ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat

ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019.

Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2

Corcept (CORT) misses earnings and revenue estimates in the second quarter of 2019.